When they released the other diabetic drug it paid off their debt and made the company more secure and attractive. Adhera imo looks like it has the Parkinson’s breakthrough?
“MLR-1019 is a mirror image molecule — called an enantiomer — of mesocarb (marketed as Sidnocarb and Sydnocarb). Mesocarb is an approved medication that extends the amount of time that dopamine is available in the body by blocking cells’ ability to reabsorb it.
Melior and Adhera expect MLR-1019 to be able to boost the efficacy of L-dopa — a common medication that the brain can convert to dopamine — better than amantadine, and without that therapy’s side effects. Of note, amantadine is an oral medication approved in the U.S. to treat dyskinesia, the involuntary, jerky movements experienced by Parkinson’s patients.
This compound was first approved in the Soviet Union in 1971 and marketed for various psychiatric and neurological conditions. Mesocarb’s Russian manufacturer discontinued its production during the recession in 2008 for reasons unrelated to the compound itself.“
News 
Market Data 
Discover 
AI
